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Aneurysmal subarachnoid haemorrhage is a neurological syndrome with complex systemic complications. The
rupture of an intracranial aneurysm leads to the acute extravasation of arterial blood under high pressure into the
subarachnoid space and often into the brain parenchyma and ventricles. The haemorrhage triggers a cascade of
complex events, which ultimately can result in early brain injury, delayed cerebral ischaemia, and systemic
complications. Although patients with poor-grade subarachnoid haemorrhage (World Federation of Neurosurgical
Societies 4 and 5) are at higher risk of early brain injury, delayed cerebral ischaemia, and systemic complications,
the early and aggressive treatment of this patient population has decreased overall mortality from more than
50 % to 35 % in the last four decades. These management strategies include (1) transfer to a high-volume centre,
(2) neurological and systemic support in a dedicated neurological intensive care unit, (3) early aneurysm repair,
(4) use of multimodal neuromonitoring, (5) control of intracranial pressure and the optimisation of cerebral
oxygen delivery, (6) prevention and treatment of medical complications, and (7) prevention, monitoring, and
aggressive treatment of delayed cerebral ischaemia. The aim of this article is to provide a summary of critical care
management strategies applied to the subarachnoid haemorrhage population, especially for patients in poor
neurological condition, on the basis of the modern concepts of early brain injury and delayed cerebral ischaemia.Background
Aneurysmal subarachnoid haemorrhage (SAH) is a com-
plex neurovascular syndrome with profound systemic ef-
fects and is associated with high disability and mortality
[1]. Despite a 17 % decrease in case fatality in the last
three decades associated with improved management
strategies, 30-day mortality and before-admission death
rate unfortunately are still high, around 35 % and 15 %,
respectively [2].
Outcomes after SAH can vary significantly, from full
recovery to severe disability or death, depending on the
severity of the initial bleed and potential complications
typically happening in the first 2 weeks after the haem-
orrhage [3]. The level of consciousness is considered the
most important early predictor of outcome [4–6]. Pa-
tients with a normal level of consciousness have a low
risk of mortality. Patients admitted with a depressed* Correspondence: airtonleo.manoel@gmail.com
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ability, although improved outcomes have also been
shown in this group of patients in the last decades. For
these reasons, patients presenting with a Glasgow Coma
Scale (GCS) score of less than 13 have traditionally been
defined as having poor-grade SAH (classified as grade 4
and 5 according to the Hunt and Hess [4] or the World
Federation of Neurosurgical Societies (WFNS) grading
scales [5] or more recently as VASOGRADE-Red [6]).
Poor outcomes are usually secondary to early brain in-
jury (EBI) or to delayed cerebral ischaemia (DCI). EBI
refers to the acute consequences of SAH-associated sud-
den increase of intracranial pressure (ICP), which can
cause decreased cerebral perfusion and transient global
cerebral ischaemia. The global cerebral ischaemia can re-
sult in transient loss of consciousness or progressive
intracranial hypertension. Subarachnoid blood itself can
also damage the brain. DCI is a multifactorial entity
often responsible for poor outcome after SAH in pa-
tients who survive the initial haemorrhage. Clinically, it
is characterised by a change in neurological functions This article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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haemorrhage. Recently, DCI was defined as a change in
level of consciousness (decrease of 2 points in the GCS
or an increase in 2 points in the National Institute of
Health Stroke Scale) or development of new focal deficit
lasting for at least 1 hour and not explained by other fac-
tors (e.g., systemic complications and hydrocephalus) [7].
DCI is believed to be due to a combination of factors such
as angiographic vasospasm, cortical spreading ischaemia,
microthrombosis, and microcirculation vasoconstriction.
In this review, we will discuss the management of patients
with poor-grade SAH on the basis of the current concepts
of EBI and delayed cerebral ischaemia.
Search strategy
A PubMed search for articles published until May 2015
was performed by using the terms “Subarachnoid
Hemorrhage” [Mesh] AND (“poor-grade” [Title/Abstract]
OR “high-grade” [Title/Abstract]), which returned 236
articles. Additionally, the reference lists of the most
recent guidelines on the management of SAH were
searched [8–10]. Lastly, the authors’ personal databases
were used as an additional source for this review.Fig. 1 Early pathophysiology of subarachnoid haemorrhage. Acute haemor
acute transient global ischaemia. Transient global ischaemia secondary to i
system activation, leading to systemic complications. The contribution of e
ischaemia and subarachnoid blood result in early brain injury, characterised
blood–brain barrier, cytotoxic and vasogenic cerebral oedema, and neuron
perfusion pressure, ECG electrocardiographic, ET-1 endothelin-1, ICH intracrania
NO nitric oxide, TNF-R1 tumour necrosis factor receptor 1. First published in Na1. Initial management: medical stabilisation,
prevention of re-bleeding, and control of intracra-
nial pressure
During aneurysmal SAH, extravasation of high-pressure
arterial blood in the subarachnoid space (and often into
the brain parenchyma and ventricles) is associated with
a sudden ICP increase that, if severe and sustained, may
compromise cerebral perfusion, causing global cerebral
ischaemia and EBI (Fig. 1). If the haemorrhage does not
stop, acute cardiopulmonary instability associated with
intracranial hypertension or compromised cerebral
blood flow (CBF) leads to patient death before hospital
admission. In patients who survive the initial haemor-
rhage, re-bleeding is the most severe early complication;
the reported incidence is up to 15 % in the first 24 hours,
and the fatality rate is approximately 70 % [11–13].
Patients with poor-grade SAH are at higher risk of re-
bleeding [14]. Initial management therefore should focus
on strategies aimed to prevent re-bleeding and to con-
trol ICP.
Early aneurysm repair is generally considered the most
important strategy to reduce the risk of aneurysm re-
rupture [15]. However, evidence for optimum timing ofrhage from an aneurysm can physically damage the brain and lead to
ncreased intracranial pressure can also trigger sympathetic nervous
ach process to the pathophysiology is unknown, but transient global
by microcirculation constriction, microthrombosis, disruption of the
al and endothelial cell death. CBF cerebral blood flow, CPP cerebral
l haemorrhage, ICP intracranial pressure, MMP-9 matrix metalloproteinase-9,
ture Reviews Neurology [95]
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treatment (less than 24 hours) is superior to early
aneurysm repair (within 72 hours). A recently published
retrospective data analysis comparing ultra-early treatment
with repair performed within 24–72 hours after haemor-
rhage suggests that aneurysm occlusion can be performed
safely within 72 hours after aneurysm rupture [16]. The
American Heart Association/American Stroke Association
[9] recommend as a Class IB Recommendation that “surgi-
cal clipping or endovascular coiling of the ruptured
aneurysm should be performed as early as feasible in the
majority of patients to reduce the rate of re-bleeding after
SAH”. This recommendation for timing of aneurysm
intervention is corroborated by the European Stroke
Organization Guidelines for the Management of Intracra-
nial Aneurysms and Subarachnoid Haemorrhage [10],
which stated that “aneurysm should be treated as early as
logistically and technically possible to reduce the risk of
re-bleeding; if possible it should be aimed to intervene at
least within 72 hours after onset of first symptoms”.
The results from an ongoing trial only enrolling patients
with poor-grade SAH may help answer the question of
whether early treatment (within 3 days) is associated with
improved outcome compared with intermediate (days 4–7)
or late (after day 7) treatment [17].
The choice of treatment modality between surgical
clipping and endovascular coiling is a complex endeav-
our, which requires the expertise of an interdisciplinary
team, including neurointensivists, interventional neuro-
radiologists and neurovascular surgeons. For aneurysms
considered to be equally treatable by both modalities,
the endovascular approach is superior, being associated
with better long-term outcomes [18–20]. Randomised
trials of clipping versus coiling included mostly good-
grade patients, leading to controversy as to whether their
results apply also to poor-grade patients. Retrospective
data on clipping and coiling in poor-grade patients seem
to suggest that surgical clipping and endovascular are
equally effective [21]. An early and short course of an
anti-fibrinolytic drug such as tranexamic acid, initiated
as soon as the radiological diagnosis of SAH is estab-
lished and stopped within 24–72 hours, has been associ-
ated with decreased rate of ultra-early re-bleeding and a
non-significant improvement in long-term functional
outcome [22]. This approach remains controversial [23],
and short-term administration of tranexamic acid to pre-
vent re-bleeding is being further studied in a multicentre
randomised trial (Dutch Trial Registry number NTR3272)
[24]. Another medical intervention applied to prevent
aneurysm re-rupture is the avoidance of extremes of blood
pressure. The American Heart Association/American
Stroke Association [9] and the Neurocritical Care [8]
guidelines suggest keeping the mean arterial blood pres-
sure below 110 mm Hg or systolic blood pressure below160 mm Hg (or both) in the presence of ruptured un-
secured aneurysm. The European guidelines are less ag-
gressive and suggest keeping the systolic blood pressure
below 180 mm Hg [10]. These parameters should not be
used after aneurysm treatment, when spontaneously high
blood pressure may be beneficial [25].
Intracranial hypertension (ICP of at least 20 mm Hg) is a
relatively common complication of SAH, especially in pa-
tients presenting with poor neurological condition [26–28].
Multiple factors such as cerebral oedema, intraparench-
ymal haematoma, acute communicating hydrocephalus,
intraventricular haemorrhage, aneurysm re-rupture,
complications related to aneurysm treatment, EBI, and
DCI can contribute to the development of intracranial
hypertension [29]. High ICP is associated with severe
derangements of cerebral metabolism [30], increased
risk of neurological deterioration [25], and poor out-
come, especially if refractory to medical treatment [29,
31]. ICP of greater than 20 mm Hg is an independent
predictor of severe disability and death in aneurysmal
SAH [30].
Principles of management of intracranial hypertension
after SAH have been traditionally adopted from trau-
matic brain injury (TBI) literature [32] and are not spe-
cifically designed for the SAH population. However,
these two entities are different from a pathophysiological
perspective, and the use of therapies tested in patients
with TBI in the SAH population is controversial. Cur-
rently, the role of therapies such as hyperosmolar agents,
hypothermia, barbiturates, and decompressive craniect-
omy is not well established in SAH patients with intra-
cranial hypertension refractory to first-line treatments.
The initial approach to raised ICP includes head of
bed elevation (between 30° and 45°) to optimise cerebral
venous drainage, normoventilation (arterial partial pres-
sure of carbon dioxide (PaCO2): 35–40 mm Hg) [33],
use of sedation and analgesia to achieve a calm and quiet
state (Richmond Agitation Sedation Scale score of −5 or
Sedation-Agitation Scale score of 1), and surgical inter-
vention in the presence of mass-occupying lesions [34].
The use of neuromuscular blocking agents is sometimes
applied to prevent ICP surges during tracheal suctioning
and physiotherapy; however, the role of these drugs for
ICP management is not well established, and some au-
thors suggest that they may be more deleterious than
beneficial [35]. If ICP remains elevated despite these inter-
ventions, a short course (less than 2 hours) of hyperventi-
lation (PaCO2 of 30–35 mm Hg) might be considered
while new brain imaging is obtained and other interven-
tions are planned and initiated [36–38].
Cerebrospinal fluid (CSF) drainage is a mainstay in
ICP management of patients with SAH, especially when
hydrocephalus is present [39]. Acute hydrocephalus is
common in SAH, and approximately 50 % of patients
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associated with a decreased level of consciousness, an
external ventricular drain (EVD) should be inserted to
allow CSF drainage and ICP monitoring. EVD insertion
before aneurysm treatment has been shown to be safe
and not associated with increased risk of aneurysm re-
rupture [40, 41], if accompanied by early aneurysm
repair. Additionally, when EVD insertion is performed
before aneurysm repair, CSF drainage should be prac-
ticed with caution because rapid and aggressive CFS
drainage can increase transmural pressure, increasing
the risk of aneurysm re-rupture [41, 42]. Interestingly,
approximately 30 % of patients with poor-grade SAH
improve neurologically after EVD insertion and CSF
drainage. These responders have a functional outcome
similar to that of good-grade (WFNS I–III) patients [39].
Hyperosmolar agents, such as mannitol and hyper-
tonic saline, are usually considered when the above strat-
egies fail to control ICP, although their role on clinical
outcome in the SAH population is not well established.
We could not identify any study addressing the role of
mannitol in the management of raised ICP in the SAH
population; for hypertonic saline, we found only case
series [43–46] and a small placebo-controlled trial in pa-
tients with raised but stable ICP [47]. In these studies,
hypertonic saline was effective to control ICP and im-
proved CBF [43–47] and may improve outcome in the
poor-grade population [43].
The last line of treatment includes the use of barbitu-
rates, induced hypothermia, and decompressive craniect-
omy [38, 48]. Therapeutic hypothermia has been shown
to be effective to control ICP in SAH but has not been
associated with improved functional outcome and re-
duced mortality rates in patients with poor-grade SAH
[49]. The association of barbiturate coma and mild
hypothermia (33–34 °C, median treatment of 7 days)
was studied in 100 SAH (64 poor-grade) patients with
intracranial hypertension refractory to other medical inter-
ventions [50]. Approximately 70 % of patients were severely
disabled or dead at 1 year, and more than 90 % of patients
developed medical complications associated with the
hypothermia/barbiturate treatment (i.e., electrolyte disor-
ders, ventilator associated pneumonia, thrombocytopenia,
and septic shock). Decompressive craniectomy is another
possible strategy for refractory ICP management in patients
with SAH. Poor-grade patients are more commonly ex-
posed to this rescue therapy than patients with good-grade
SAH [51, 52]. Decompressive craniectomy has been associ-
ated with decreased mortality [53], significant reduction of
ICP [34], improved cerebral oxygenation [54, 55], and im-
proved cerebral metabolism [56]. However, most patients
undergoing decompressive craniectomy due to refractory
ICP have poor outcome, with severe disability or death
[56]. Many authors suggest that, if any benefit can beachieved with decompressive craniectomy, this may be best
obtained when the procedure is performed early (within
48 hours from the bleeding) [52] and in the absence of
radiological signs of cerebral infarction [51]. Finally, in
poor-grade patients with large intraparenchymal or Sylvian
fissure haematomas usually from middle cerebral artery an-
eurysms, prophylactic decompressive craniectomy should
be considered [34].
It is important to mention that long-term outcome
after acute brain injury is markedly improved when pa-
tients are managed in a dedicated neurologic/neurosur-
gical intensive care unit (ICU) [57, 58]. Especially after
SAH, outcome is affected by hospital caseload, and bet-
ter outcomes happen in high-volume centres (centres
treating more than 60 patients per year) [59]. Six-month
mortality is inversely associated with hospital annual
caseload; there is a 24 % reduction in mortality for each
100 patients admitted per year [60]. Regardless of initial
grade, early transfer to a high-volume centre is safe and
cost-effective and should be pursued [61–63].
2. Prevention, detection, and treatment of
delayed cerebral ischaemia
Delayed neurological deterioration occurs frequently in
the first 2 weeks after SAH. Common causes of this
deterioration include neurological events such as pro-
gression of EBI, hydrocephalus, seizures, ischaemia, and
systemic conditions, such as fever and infections, re-
spiratory failure, and electrolyte abnormalities. Any de-
layed neurological deterioration presumed to be related
to ischaemia that persists for more than 1 hour and can-
not be explained differently has been defined as DCI [7]
(Table 1). DCI occurs in up to 30 % of SAH patients sur-
viving the initial haemorrhage. It can present as an acute
or insidious change in the level of consciousness or as a
focal neurological symptom, such as aphasia or hemipar-
esis, or as both. These symptoms can be reversible if
treated promptly and aggressively; otherwise, DCI tends
to progress to cerebral infarction, which is associated with
higher rates of disability and mortality. Traditionally, DCI
has been considered to be related to a cerebral vasocon-
striction (angiographic vasospasm) that begins approxi-
mately 3 days and peaks 1 week after the haemorrhage
and starts resolving after 2 weeks [64]. However, recent
evidence suggests that DCI is a complex, multifactorial
syndrome, which can include additional pathophysiologic
processes beyond angiographic or sonographic vasospasm
(Fig. 2 and Table 2) [65]. DCI may also occur in cerebral
territories without evidence of angiographic vasospasm
[66]. EBI (defined as brain injury developing in the first
72 hours after haemorrhage) has significant impact on
likelihood and severity of subsequent ischaemic changes
[67, 68]. For example, poor-grade patients, who have
worse EBI, as well as patients who lose consciousness at
Table 1 The current definitions of early brain injury, delayed
cerebral ischaemia, and cerebral infarction
A. Early brain injury is the acute consequence of subarachnoid
haemorrhage (SAH) that leads to transient global cerebral ischaemia
following the aneurysm rupture. During aneurysmal rupture, arterial
blood leaks under high pressure into the subarachnoid space and
often into the brain parenchyma and ventricles. There is an acute and
sharp increase in the intracranial pressure (ICP) that may rise high
enough to compromise cerebral perfusion, causing global cerebral
ischaemia. This acute drop in cerebral perfusion pressure usually
produces loss of consciousness. The initial cerebral injury (i.e., early
brain injury) is the combined result of transient global cerebral
ischaemia and the effects of the subarachnoid blood itself.
B. Global cerebral ischaemia: As discussed above, the aneurysm rupture
leading to SAH can increase the ICP to cause global cerebral
ischaemia. If the haemorrhage does not stop, the patient dies before
hospital admission and this is usually due to acute cardiopulmonary
changes associated with the high ICP or due to brain death related to
the compromised cerebral blood flow. Re-bleeding remains the most
important complication in the hours following the initial bleed. There-
fore, the initial management should focus on strategies to prevent
aneurysm
re-bleeding and to control ICP.
C. Delayed cerebral ischaemia (DCI) is defined as “the occurrence of focal
neurological impairment (such as hemiparesis, aphasia, apraxia, hemian-
opia, or neglect), or a decrease of at least 2 points on the Glasgow Coma
Scale (either on the total score or on one of its individual components,
such as eye, motor on either side, or verbal). This should last for at least
1 hour, is not apparent immediately after aneurysm occlusion, and
cannot be attributed to other causes by means of clinical assessment, CT
or MRI scanning of the brain, and appropriate laboratory studies” [7]. DCI
remains the most significant cause of long-term disability and mortality
in patients who survive the initial haemorrhage to reach definitive
aneurysm treatment [170]. In those patients who survive the initial bleed
to reach medical assistance, the degree of brain injury associated with
transient global cerebral ischaemia is variable. However, the main factor
associated with the degree of injury and long-term outcome is ultimately
the level of consciousness. Patients with small haemorrhages at the time
of aneurysm rupture usually do not develop transient cerebral ischaemia
and do not lose consciousness; however, they are still at risk of DCI [171].
On the other hand, patients who transiently lose consciousness have
probably had a transient global ischaemic event and are at a higher risk
of DCI [67].
D. Cerebral infarction caused by DCI is defined as “the presence of cerebral
infarction on computed tomography or magnetic resonance scan of the
brain within 6 weeks after SAH, or on the latest scan made before death
within 6 weeks, or proven at autopsy, not present on the computed
tomography or magnetic resonance scans between 24 and 48 hours
after early aneurysm occlusion, and not attributable to other causes
such as surgical clipping or endovascular treatment. Hypodensities
on computed tomography imaging resulting from ventricular catheter
or intraparenchymal haematoma should not be regarded as cerebral in-
farctions from DCI” [7].
CT computed tomography, MRI magnetic resonance imaging
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sode of transient global cerebral ischaemia) have increased
risk of DCI [67, 68].
Cortical spreading ischaemia (CSI) is a wave of depolar-
isation in the grey matter that propagates across the brain
at 2–5 mm/minute [69, 70], leading to depression in
evoked potentials and spontaneous electroencephalogram
activity. The use of invasive subdural electrocorticographic
monitoring combined with regional CBF measurements
has shown that CSI can occur isolated or in clusters, and
the depolarisation waves are associated with profoundcortex hypoperfusion secondary to vasoconstriction [71].
The vast majority of cortical spreading depolarisation
waves usually happen in the first 2 weeks after aneurysm
rupture, and 75 % of all CSIs recorded occur between the
fifth and seventh day post-bleeding [72]. In a prospective
multicentre study, Dreier et al. [73] assessed the incidence
and timing of spreading depolarisations and DCI after
SAH. Eighteen SAH patients requiring craniotomy for
aneurysm treatment were monitored for up to 10 days
with subdural electrodes. Cortical spreading depolarisa-
tions were detected in 13 patients (72 %). DCI was de-
tected in seven patients and was time-locked to a
sequence of recurrent spreading depolarisations in all
seven cases. Additionally, delayed ischaemic strokes
verified by serial computed tomography (CT) scans or
magnetic resonance imaging occurred in the recording
area in four patients. In another prospective study,
using a novel subdural opto-electrode technology for
simultaneous laser-Doppler flowmetry and direct
current-electrocorticography, combined with measure-
ments of tissue partial pressure of oxygen, Dreier et al.
[71] studied 13 patients with SAH. Isolated spreading
depolarisations were detected in 12 of those. These
waves of depolarisations were associated with physio-
logical, absent, or inverse regional CBF responses. Normal
haemodynamic response was associated with tissue hyper-
oxia, whereas inverse response led to tissue hypoxia. Five
patients presented clusters of prolonged spreading depo-
larisations with persistent depressions. These clusters of
spreading depolarisations were closely associated with
structural brain damage as observed by neuroimaging.
Similarly, Bosche et al. [72] have reported low cerebral
measurements of tissue partial pressure of oxygen occur-
ring during clusters of spreading depolarisations.
Microthrombosis is common after SAH [74]. Subarach-
noid blood and blood products activate inflammatory
pathways, along with tissue factor in the microcirculation
of cerebral vessel wall, leading to endothelial cell activation
and damage, which in turn cause mural thrombus forma-
tion and release of microemboli [75]. Markers of increased
activity of the coagulation cascade have been associated
with DCI, cerebral infarction, and poor outcome [76]. For
example, in a group of 90 patients with SAH, early (within
3 days of SAH onset) elevated concentrations of von Will-
ebrand factor were associated with poor outcome (crude
odds ratio (OR) = 4.6, 95 % confidence interval (CI) 2.0–
10.9; adjusted OR = 3.3, 95 % CI 1.1–9.8), ischaemic events
(crude hazard ratio (HR) = 2.3, 95 % CI 1.1–4.9; adjusted
HR = 1.8, 95 % CI 0.8–3.9), and occurrence of spontaneous
DCI (crude HR = 3.5, 95 % CI 0.9–13.1; adjusted HR = 2.2,
95 % CI 0.5–9.8). The hypothesis is that this early elevation
in von Willebrand factor levels probably reflects the forma-
tion of microthrombi in the cerebral circulation [77, 78].
Autopsy studies have shown that patients who developed
Fig. 2 Pathophysiological processes in delayed cortical ischaemia. Key processes include angiographic vasospasm, microcirculatory constriction and
formation of microthrombi, and waves of cortical spreading ischaemia, all of which can contribute to cerebral infarction. Delayed effects of the early
brain injury such as neuronal and endothelial cell apoptosis, and systemic complications, can also occur. CPP cerebral perfusion pressure, ICP
intracranial pressure, NO nitric oxide, SAH subarachnoid haemorrhage, TRP transient receptor potential. First published in Nature Reviews Neurology [95]
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microthrombi compared with SAH patients who died be-
cause of re-bleeding or acute hydrocephalus [75, 79].
Haptoglobin is a complex tetramer glycoprotein, con-
sisting of two α and two β chains, synthesised mainly byTable 2 Facts that challenged the concept of angiographic
vasospasm as the main factor leading to delayed cerebral
ischaemia
A. Approximately 70 % of patients with subarachnoid haemorrhage (SAH)
will develop some degree of angiographic vasospasm within 2 weeks of
haemorrhage [64, 165]; however, only 30 % will develop symptoms (i.e.,
delayed cerebral ischaemia, or DCI) [88].
B. DCI-associated cerebral infarct is an independent factor for poor
outcome after SAH [166]; however, cerebral infarction can happen
asymptomatically [88] or in vascular territories not affected by
vasospasm [167].
C. Large-vessel angiographic vasospasm detected by modalities such
as transcranial Doppler has a poor temporal relationship with the
development of DCI [167].
D. There is no evidence that nimodipine decreases the rate of angiographic
vasospasm or promotes cerebral vasodilation; however, it remains the
sole pharmacological intervention proven to improve outcomes
from DCI [108, 111].
E. There is an important dissociation between vasospasm-related
morbidity and functional outcome after SAH [168, 169].
F. The prevention and treatment of angiographic vasospasm do not
necessarily translate into improved outcome [169].the liver [80]. It is an acute-phase protein that increases
in plasma during major stress situations, such as sepsis,
burns, and major trauma. Some recent studies have sug-
gested that the haptoglobin α1-α1 isoform could be pro-
tective after SAH [81–83]. Haptoglobin binds free
extracellular haemoglobin, which reduces free haemo-
globin ability to generate oxygen-free radicals and there-
fore interferes in one of the possible pathophysiological
pathways of angiographic vasospasm (i.e., haemoglobin-
mediated oxidative stress) [82].
Kantor et al. [82] found, in a cohort of 193 patients
with SAH, that the haptoglobin α2-α2 isoform was asso-
ciated with worse functional outcome at 3 months when
compared with the α1-α1 genotype. The haptoglobin
α2-α2 isoform has a lower affinity for binding haemoglo-
bin and possibly inhibits haptoglobin-haemoglobin clear-
ance because of its larger size [84]. The α2-α2 genotype
remained significantly associated with worse functional
outcome (OR 4.138; P = 0.0463) after adjustment for age,
sex, Fisher grade, and Hunt and Hess grade. A previous
study had already shown that haptoglobin α2-α2 geno-
type was associated with higher rates of angiographic
vasospasm by transcranial Doppler (TCD) and conven-
tional angiography performed between days 3 and 14
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showed, in a cohort of 74 patients with SAH, that hapto-
globin α2-α2 genotype was an independent risk factor
for the development of focal and global angiographic
vasospasm and also predictive of unfavourable functional
outcomes and mortality.
The hypothesis is that patients with haptoglobin α2-α2
genotype do worse because of reduced CSF clearance of
haemoglobin, increased reactive oxygen species, and
therefore development of more inflammation. This hy-
pothesis is corroborated by an experimental model of
SAH, which showed that mice expressing human α2-α2
haptogobin developed more severe angiographic vaso-
spasm and increased macrophage/neutrophil counts in
the CSF after SAH, when compared with wild-type α1-
α1 haptogobin-expressing mice [85]. Although there is
no clinical intervention directly designed to address this
important recent finding on the pathophysiology of
SAH, the genetic effect on outcome after SAH may in-
crease our knowledge of the disease.
Delayed cerebral ischaemia monitoring. Triggers for
detection and confirmation of delayed cerebral ischaemia
in sedated or poor-grade patients
Figure 3 summarises a possible approach for the man-
agement of SAH patients in poor neurological condition.
The key management of patients with acute brain injury,
including the SAH population, is the minimisation of a
complex cascade of ischaemic and apoptotic cellularFig. 3 Summary of a possible approach for the management of subarachn
respiratory distress syndrome, BP blood pressure, CPP cerebral perfusion pre
angiography/computed tomography perfusion, DCI delayed cerebral ischaem
Scale, Hgb haemoglobin, HOB head of bed, ICH intracerebral haemorrhage, IC
intravenously, IVH intraventricular haemorrhage, MAP mean arterial pressure, M
NeuroICU neurointensive care unit, NIHSS National Institutes of Health Stroke S
oxygen saturation, SBP systolic blood pressure, SIADH syndrome of inappropri
computed tomography, T temperature, VTE venous thromboembolism, WFNSevents, oedema, and excitotoxicity that can result in de-
layed and often progressive secondary brain injury. Un-
like primary injury, this delayed damage is considered, at
least partially, preventable or reversible if adequately
treated. Its prevention, timely detection, and appropriate
management require an early, aggressive, and well-
structured approach to patient care. This is especially
true in patients with poor-grade SAH, where limited
neurological examination and a higher incidence of sys-
temic complications make DCI identification a signifi-
cant challenge.
DCI is often a diagnosis of exclusion; confounding fac-
tors such as hypoxia, electrolyte disturbances, infection,
fever, hydrocephalus, convulsive, and non-convulsive sei-
zures can produce delayed neurological deterioration
similar to that of DCI and should always be considered
in the differential and treated accordingly. Moreover, in
the poor-grade SAH population, new neurological defi-
cits are clinically difficult to detect because of decreased
level of consciousness and the frequent need for sed-
ation (usually required for ICP and mechanical ventila-
tion management), making the detection of acute
neurological deterioration even more challenging. Pa-
tients who require sedation but who are clinically stable
(i.e., absence of ICP crisis, cardiopulmonary instability,
or status epilepticus) should undergo interruption of
sedation and analgesia (i.e., neurological wake-up tests)
that could detect focal neurological deficits. Wake-up
tests seem to be safe since they are not associated withoid haemorrhage patients in poor neurological condition. ARDS acute
ssure, CSF cerebrospinal fluid, CTA/CTP computed tomography
ia, DSA doxyl stearic acid, ECG electrocardiogram, GCS Glasgow Coma
P intracranial pressure, IPC intermittent pneumatic compression, iv
RI/MRA magnetic resonance imaging/magnetic resonance angiography,
cale/Score, PaCO2 arterial partial pressure of carbon dioxide, SaO2 arterial
ate secretion of antidiuretic hormone, SPECT single-photon emission
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sured by microdialysis and direct brain tissue oxygen-
ation measurement, respectively [86]. However, the
sensitivity of neurological examination to detect signs of
DCI in the setting of poor-grade SAH is low [87]; ap-
proximately 20 % of patients who develop DCI, as iden-
tified by new infarctions on CT or magnetic resonance,
do not have any evidence of clinical neurological deteri-
oration [88, 89]. Interestingly, these patients who devel-
oped “asymptomatic” cerebral infarctions were less likely
to receive vasopressor agents and had higher frequency
of death or moderate-to-severe disability than those with
“symptomatic” DCI [88].
Because neurological examination is less useful in this
setting, a suspicion of DCI will frequently be based on
changes detected by screening tools. According to the
Neurocritical Care Guidelines on the management of SAH,
“in sedated or poor-grade SAH patients, clinical deterior-
ation may be difficult to assess, and transcranial Doppler
(TCD), continuous electroencephalography (cEEG), brain
tissue oxygen pressure (PtiO2) monitoring, and/or cerebral
microdialysis (CMD) are options for monitoring for vaso-
spasm and DCI”. Changes commonly used to trigger inter-
vention include the following [8, 90]:
1. An increase in either (a) TCD mean flow velocity in
the middle cerebral artery (FVMCA) of more than
50 cm/second over 24 hours or (b) mean FVMCA
of at least 200 cm/second or middle cerebral artery/
internal carotid artery ratio of more than 6 or both [8].
2. 2. CT perfusion parameters: CBF of less than 25 ml/
100 g/minute or mean transit times (MTTs) of more
than 6.5 seconds or both [91].
3. Severe angiographic vasospasm (defined as a
narrowing of at least 70 % from baseline) [92]
detected by digital subtraction angiography (i.e., gold
standard) or CT angiography (which is also highly
specific for angiographic vasospasm).
4. Electroencephalography (EEG) reduced alpha
variability [93].
5. Abnormal levels of brain tissue oxygen (PtiO2 of less
than 20 mm Hg; Fig. 4) or CMD (i.e., lactate/pyruvate
ratio (LPR) of more than 40 and glucose of less than
0.5 mM and in second line for glutamate of more
than 40 mM) or both [93].
Multimodal neuromonitoring
Modalities capable of monitoring CBF (e.g., CT perfu-
sion or CTP), cerebral oxygenation (e.g., brain tissue
oxygen catheter), and cerebral metabolism (e.g., microdi-
alysis) are theoretically superior to modalities monitor-
ing exclusively vessel diameter (e.g., TCD, conventional
angiography, and CT angiography, or CTA). We have
previously published a possible approach combining theuse of TCD and multimodal CT [94, 95] for monitoring
patients with SAH in accordance with the VASOGRADE
[6]. It is important to mention that, in the poor-grade
population, if screening CTA or digital subtraction angiog-
raphy has already recognised the presence of severe angio-
graphic vasospasm in a setting of acute neurological
deterioration, it is reasonable to start empiric DCI therapy
without additional neurological investigation. Additionally,
when screening CTP demonstrates perfusion deficits
(CBF of less than 25 ml/100 g/minute or MTT of more
than 6.5 seconds or both) [91], it is reasonable to initiate
therapy for DCI.
ICP and cerebral perfusion pressure (CPP) monitoring
have been the cornerstone parameters in the manage-
ment of comatose patients with acute brain injury. Crit-
ical levels of CPP (of less than 70 mm Hg) have been
significantly associated with cerebral infarction [96] after
SAH. Also, CPP of less than 60 mm Hg has been associ-
ated with higher ICP levels and abnormal levels of PtiO2
and LPR [97]. However, recent clinical data suggest that
cerebral hypoxia (PtiO2 of less than 20 mm Hg) and
cerebral energy dysfunction (LPR of more than 40) may
occur despite normal levels of ICP and CPP in the poor-
grade SAH population [97].
Chen et al. [97], in a cohort of 19 patients with poor-
grade SAH, demonstrated that ICP and CPP monitoring
may not be sufficient to detect episodes of cerebral com-
promise, such as severe brain hypoxia detected by PtiO2
catheter (PtiO2 of not more than 10 mm Hg) or brain
energy dysfunction detected by CMD (LPR of at least
40). The sensitivities of abnormal ICP or CPP levels for
elevated LPR and reduced PtiO2 were 21.2 %, and critical
levels of LPR or PtiO2 were found on many occasions
when ICP or CPP was normal. Additionally, early brain
tissue hypoxia (i.e., within 24 hours of haemorrhage) is
very prevalent in the poor-grade SAH population [98].
Therefore, the use of multimodal neuromonitoring may
be a good complement to ICP/CPP monitoring, which
could detect cerebral oxygen or energy compromise in
an early reversible state [93] (Fig. 4).
Continuous electroencephalography monitoring in patients
with poor-grade subarachnoid haemorrhage
Continuous EEG (cEEG) has been described as a useful
monitoring tool for the prediction and diagnosis of
angiographic vasospasm and DCI. Also, cEEG findings
may be a prognostic marker in patients with poor-
grade SAH [99, 100]. Several studies have investigated
and demonstrated a positive correlation between cEEG
findings and angiographic vasospasm, DCI, and functional
outcome [99–102], supporting the critical care use of
this modality in poor-grade or sedated SAH patients.
Commonly described quantitative cEEG findings that
predict angiographic vasospasm or DCI are (a) decreased
Fig. 4 (See legend on next page.)
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Fig. 4 Approach to low brain tissue oxygen. Consider the combined used of PtiO2 and microdialysis catheter to detect non-hypoxic patterns of
cellular dysfunction [97]. According to the manufacturer, an equilibrium time as long as 2 hours may be necessary before PtiO2 readings are
stable, because of the presence of the tip surrounding microhaemorrhages. Sensor damage may also occur during insertion. Increase inspired
fraction of oxygen (FiO2) to 100 %. If PtiO2 increases, it confirms good catheter function. Oxygen challenge to assess tissue oxygen reactivity. FiO2
is increased from baseline to 100 % for 5 minutes to evaluate the function and responsiveness of the brain tissue oxygen probe. A positive
response happens when PtiO2 levels increase in response to higher FiO2. A negative response (lack of PtiO2 response to higher FiO2) suggests
probe or system malfunction. Another possibility if there is a negative response is that the probe placement is in a contused or infarcted area.
Follow-up computed tomography might be necessary in this situation to ensure appropriate probe position. Mean arterial pressure (MAP)
challenge to assess cerebral autoregulation. MAP is increased by 10 mm Hg. Patients with impaired autoregulation demonstrated an elevation in
ICP with increased MAP. When the autoregulation is intact, no change or a drop in ICP levels follows the elevation in blood pressure. Another
way to assess cerebral autoregulation is the evaluation of the index of PtiO2 pressure reactivity. When autoregulation is intact, PtiO2 is relatively
unaffected by changes in CPP, so the index of PtiO2 pressure reactivity is near zero [163]. The threshold haemoglobin (Hgb) of 9 mg/dl to indicate
blood transfusion was based on a previously published PtiO2 study [164]. CPP cerebral perfusion pressure, CSF cerebrospinal fluid, CT computed
tomography, ICP intracranial pressure, PaCO2 arterial partial pressure of carbon dioxide, PaO2 partial pressure of oxygen in arterial blood, PtiO2 brain
tissue oxygen pressure, RASS Richmond Agitation-Sedation Scale, SAH subarachnoid haemorrhage, SBP systolic blood pressure
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delta ratio [100, 102]. Other cEEG findings such as peri-
odic epileptiform discharges, electrographic status epilep-
ticus, and the absence of sleep architecture have been
described as independent prognostic factors in the poor-
grade SAH population after adjustment for known prog-
nostic factors such as age, clinical grade (i.e., Hunt and
Hess grade), and the presence of intraventricular haemor-
rhage [99]. Claassen et al. [99] described, in a cohort of
116 patients with SAH, that the absence of sleep architec-
ture (80 % versus 47 %; OR 4.3, 95 % CI 1.1–17.2) and the
presence of periodic lateralised epileptiform discharges
(PLEDs) (91 versus 66 %; OR 18.8, 95 % CI 1.6–214.6)
were associated with 3-month poor outcome by modified
Rankin scale. Additionally, all patients with absent EEG
reactivity, generalised periodic epileptiform discharges,
and bilateral independent PLEDs and 92 % of patients (11
out of 12) with non-convulsive status epilepticus pro-
gressed to have a poor functional outcome at 3 months.Monitoring brain tissue partial pressure of oxygen
The invasive monitoring of brain tissue oxygenation al-
lows regional and continuous monitoring of PtiO2,
which may detect early changes in cerebral tissue oxy-
genation that precede ischaemic damage. PtiO2 levels of
below 20 mm Hg require attention and might be a
warning sign of ischaemia not detected clinically. PtiO2
levels of below 15 mm Hg require immediate interven-
tion to optimise cerebral tissue oxygenation (Fig. 4).
PtiO2 levels have been directly correlated with the de-
velopment of ischaemic events [96], angiographic vaso-
spasm [103], and outcome [104]. In addition to PtiO2
monitoring, the use of CMD may be a possible alterna-
tive for monitoring sedated or poor-grade patients at risk
of DCI. The combined use of PtiO2 and CMD catheter
can help discriminate two patterns of cellular dysfunction
(i.e., hypoxic and non-hypoxic cellular dysfunction) [97].CMD measures the interstitial levels of several sub-
stances, such as glucose, lactate, pyruvate, glutamate,
glycerol, and several inflammatory biomarkers. An in-
creased LPR is the most common and better-studied
marker of anaerobic cerebral metabolism and therefore
is an indicator of cerebral ischaemia [93]. Metabolic
changes detected by CMD, such as elevated LPR, have
been shown to predict delayed neurological deterioration
and “symptomatic vasospasm” [105, 106]. Also, extreme
microdialysate values of lactate, glutamate, LPR, and gly-
cerol have been associated with cerebral infarction and
permanent neurological deficits [107].Pharmacological prophylaxis
Table 3 summarises drugs investigated and under investi-
gation for prevention of DCI. According to the American
Heart Association, the Neurocritical Care Society, and the
European guidelines [8–10], nimodipine, an L-type dihy-
dropyridine calcium channel antagonist, is the only medi-
cation proven to improve outcomes after SAH [108]. The
concept that nimodipine decreases the rate of angio-
graphic vasospasm has been challenged, and the mecha-
nisms by which it improves patient outcome in a setting
of SAH are not completely established.
Nimodipine probably has a neuroprotective action by
decreasing the influx of calcium after cerebral ischae-
mia due to DCI. Additionally, nimodipine might de-
crease the incidence of microthrombi by increasing the
endogenous fibrinolysis [109] and may antagonise cor-
tical spreading ischaemia [110]. Nimodipine seems to
improve long-term outcome in the poor-grade popula-
tion as well [111]. A multicentre, randomised placebo-
controlled double-blind trial studied the effect of nimo-
dipine in 188 patients with poor-grade SAH (Hunt and
Hess grade 3–5) [111]. The treatment was associated
with an improvement in functional outcome at 3 months
(29.2 % in the nimodipine group versus 9.8 % in the
Table 3 Evidence review of drugs used in aneurysmal subarachnoid haemorrhage
Drug Direct drug action Possible mechanisms of action Status Guidelines [8–10]
Nimodipine [108] L-type calcium
channel antagonist
• Reduction of angiographic
vasospasm
• Increase in fibrinolytic
activity
• Neuroprotection
• Inhibition of cortical
spreading ischaemia
Meta-analysis of clinical trials
found that oral nimodipine
reduced the risk of DCI and
poor outcome.
Class I, level A
Nimodipine should be
administered enterally
(60 mg every 4 hours) to
prevent DCI.
The only drug approved
for SAH in the USA and
Europe.





• Four randomised clinical trials
and a meta-analysis
• Clazosentan reduced angio
graphic vasospasm without a
significant effect on outcome.
• Hypotension and pulmonary
complications associated with
the drug use could have
counteracted the beneficial








for patients with SAH, as a




contraction and inhibits TNF-
induced IL-6 release from
C6 glioma cells
• Eight randomised clinical trials
• Treatment significantly
reduced the incidence of
angiographic vasospasm and
cerebral infarction and
improved the odds ratio for
good recovery compared with
placebo or nimodipine and
other drugs.
Not addressed
The drug is approved for
use in patients in Japan
and China but not in
Europe or USA.
Statins [118–120] Inhibit HMG-CoA
reductase







• Seven randomised clinical
trials of statins in patients with
SAH.
• An additional study showing
no benefit of higher dose of
simvastatin (80 mg versus
40 mg)
• One systematic review not
including the STASH trial found
no effect of statin treatment on
poor outcome.
Guidelines published before
the STASH trial [118].
The recommendations will
probably remain the same
to administer statins only if
the patient was already
receiving them at time of
SAH, as a Class I, level A.







• Protect the blood–brain barrier
• Reduce cerebral oedema
• Anticonvulsant (N-methyl-D-
aspartate receptor antagonism)
• Seven randomised clinical
trials
• Meta-analysis reported no
effect of magnesium on poor
outcome




Dantrolene [173] Inhibits ryanodine
receptors
Reduces intracellular calcium
release in smooth muscle and
may be neuroprotective
• One small dose-escalation
study
• Dantrolene in a dose of
2.5 mg/kg, administered over











Fibrinolytic agents The rapid clearance of
subarachnoid clot could reduce
angiographic vasospasm and
complications, such as cortical
spreading ischaemia and
microthrombosis.
• Five RCTs and a meta-analysis
• Thrombolysis was associated






Further trials are needed.
Standardisation
of techniques and









• Seven randomised clinical trials
and a meta-analysis found trends
toward reduction in poor outcome
Not addressed
Further trials are needed.
According to the meta-
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but also toward increased
intracranial haemorrhage.
• Only ticlopidine was associated
with statistically significant fewer
occurrences of a poor outcome
(only one small RCT)
analysis results, treatment
with antiplatelet agents to
prevent DCI or poor
outcome cannot be
recommended.
Albumin [176] Multiple Neuroprotective • One open-label dose-escalation
trial
• Trend toward improved
outcome with 1.25 g/kg per day
Not addressed
Remains experimental
Erythropoietin [177, 178] Multiple • Prevent loss of autoregulation
• Reduce angiographic vasospasm
• Inhibits apoptosis and stimulates
neurogenesis and angiogenesis
• Two RCTs
• One negative study
and one showing that patients
who received erythropoietin had
fewer cerebral infarcts, shorter
duration of autoregulatory









• Anti-smooth muscle proliferation
• Inotropic and chronotropic effects
• One small (109 patients)
randomised, single-blind study
• Cilostazol significantly reduced
angiographic vasospasm, DCI,
and cerebral infarction but had
no effect on outcome.
Not addressed
Remains experimental
CONSCIOUS Clazosentan to Overcome Neurological Ischaemia and Infarction Occurring After Subarachnoid Haemorrhage, DCI delayed cerebral ischaemia, IL-6
interleukin-6, RCT randomised controlled trial, SAH subarachnoid haemorrhage, STASH simvastatin in aneurysmal subarachnoid haemorrhage, TNF tumour
necrosis factor
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angiographic vasospasm found in the follow-up angiog-
raphy (64.3 % in the nimodipine group versus 66.2 % in
the placebo group). However, in the sub-group of grade 5
patients, no difference in functional outcome between
nimodipine and placebo groups was found [111].
Interestingly, in the poor-grade population, the admin-
istration of nimodipine is associated with an acute drop
in the mean arterial pressure and CPP, which is trans-
lated into a decrease in CBF and brain tissue oxygen-
ation [112, 113]. However, there is no prospective study
that evaluates the long-term consequences of these
physiological changes on functional outcome.Magnesium
Magnesium is a calcium channel antagonist with potent
vasodilator and neuroprotective properties. Animal
models of SAH have shown reversal of cerebral arterial
vasoconstriction, leading to reduction of the size of is-
chaemic lesions [114]. Additionally, magnesium may de-
crease the rate and frequency of cortical spreading
ischaemia [115]. Unfortunately, a large clinical trial com-
bined with a meta-analysis [116] showed no clinical
benefit with the use of magnesium infusion, measured as
favourable outcome at 6 months, incidence of DCI, or
cerebral infarction. A possible explanation is that high
levels of plasma magnesium are associated with worse
clinical outcomes [117].Statins
There is great interest in the impact of statins in the
prevention of DCI. Statins preserve endothelial func-
tion by increasing nitric oxide synthesis while decreas-
ing the synthesis of endothelin-1. Also, there are other
statin effects that may be interesting in the SAH set-
ting, such as anti-inflammatory, antioxidant, and anti-
thrombotic effects. Additionally, statins have described
neuroprotective and neurorestorative action. So far, six
randomised clinical trials [118] of statins in patients
with SAH have been published; however, a systematic
review of these studies found no effect of statin treat-
ment on poor outcome; mortality was 10 % in the statin
group versus 21 % in controls (relative risk 0.62, 95 %
CI 0.36–1.06); DCI was significantly reduced in the sta-
tin group. The overall quality of these studies was
judged to be low to moderate. Recently, two multicen-
tre randomised clinical trials were published. One com-
pared two different regimens of simvastatin (80 versus
40 mg), which showed no effect of higher dose on DCI,
modified Rankin disability score at 3 months, and an
analysis of cost-effectiveness [119]. The second study
had previously shown no benefit in the use of 40 mg
simvastatin compared with placebo for long-term out-
come, as measured by modified Rankin score at
6 months [120]. Mortality and favourable outcome were
similar in both simvastatin and placebo groups (10 %
versus 9 % and 58 % versus 62 %, respectively). Serious
adverse events were also similar in both groups (18 %)
[120]. Therefore, the guidelines will probably keep their
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tient was already receiving them at the time of SAH
[118].
Haemodynamic prophylaxis
The use of prophylactic hypervolemia, a component of
so-called triple-H therapy (hypervolemia, hypertension,
and haemodilution), is not recommended [8–10], based
on lack of evidence that it positively affects functional
outcome. It also increases the costs and risk of systemic
complications, such as cardiac dysfunction, pulmonary
oedema, and infection [121, 122].
Delayed cerebral ischaemia treatment
Haemodynamic manipulation, what is known as the
triple-H therapy, has for decades been the cornerstone
of DCI management [94, 95]. However, the literature
supporting its safety and efficacy is scarce [123]. Angio-
graphic vasospasm, in the absence of DCI, should not
be treated [90, 124]. The development of a new focal
deficit or a decrease in level of consciousness, not ex-
plained by other causes (e.g., hydrocephalus or re-
bleeding), should prompt aggressive treatment [90,
124]. A fluid bolus with normal saline might be the first
step because it increases CBF in areas of cerebral is-
chaemia [125]. The main goal is to maintain euvolemia
and normal circulating blood volume. Hypervolemia
and haemodilution do not improve cerebral oxygen de-
livery and may be associated with adverse events [121,
122]. Patients who fail to completely reverse the new
deficit after a fluid challenge may undergo a trial of
hypertension unless the blood pressure is elevated at
baseline or in the presence of heart failure [9]. Blood
pressure is augmented in a step-wise fashion by the use
of a vasopressor, typically noradrenaline [8, 126]. The
neurologic examination is repeated frequently in each
blood pressure step (180 mm Hg/190 mm Hg/200 mm
Hg), and the target should be based on clinical im-
provement. If the neurological deficit persists after the
induction of hypertension (typically up to a systolic
blood pressure of 200 to 220 mm Hg), a rescue therapy
with cerebral angioplasty or intra-arterial infusion of a
vasodilator might be of benefit [127]. The prophylactic
use of angioplasty is not associated with improved out-
come and might be associated with increased risk of arter-
ial rupture and is not recommended [128].
Medical complications
It is well described that medical complications after
SAH have a negative impact on survival and functional
outcome. Up to 80 % of patients will develop a serious
medical complication during phase 2, increasing the risk
for secondary brain injury [129].Cardiac complications following SAH can range from
benign electrocardiogram changes to overt cardiogenic
shock requiring intra-aortic balloon pump [130, 131].
Positive troponin is a good marker of left ventricular
dysfunction after SAH [132], which increases the risk of
hypotension, pulmonary oedema, and cerebral infarc-
tion [133]. The treatment is mainly supportive, and
most of the cases will recover spontaneously within
2 weeks [134]. However, aggressive ICU management
may be required in the setting of severely impaired left
ventricular function and DCI. Thus, the use of ino-
tropic agents such as dobutamine [135], levosimendan
[136], milrinone [137], and even intra-aortic balloon
pump counterpulsation [138] has been described and
can be considered to optimise the cardiac function in
order to improve CBF.
Patients with poor-grade SAH are at higher risk of car-
diac and pulmonary complications [139]. Additionally,
hypovolemia and pulmonary oedema are common phe-
nomena in this population, increasing the risk for de-
layed cerebral ischaemia [140, 141]. Therefore, the poor-
grade SAH population may benefit from advanced
haemodynamic monitoring. Yoneda et al. [139], in a
multicentre prospective cohort study of haemodynamic
monitoring using a transpulmonary thermodilution sys-
tem (PiCCO Plus), which included a group of 138 pa-
tients with poor-grade SAH, showed that extravascular
lung water index (P = 0.049), pulmonary vascular perme-
ability index (P = 0.039), and systemic vascular resistance
index (P = 0.038) were significantly higher in the poor-
grade group when compared with the good-grade popu-
lation. Additionally, poor-grade patients displayed sig-
nificantly lower cardiac index on days 1 and 2 (P = 0.027
and P = 0.011, respectively) and developed heart failure-
like afterload mismatch at an early stage, and those who
developed DCI had haemodynamic measures of hypovol-
emia, as shown by a decreased global end-diastolic volume
index [139]. The same group described the mean global
end-diastolic volume index (normal range, 680–800 ml/
m2) as an independent factor for the development of DCI
(HR 0.74, 95 % CI 0.60–0.93; P = 0.008). Patients who de-
veloped DCI had significantly lower global end-diastolic
volume index compared with patients who did not (783 ±
25 ml/m2 versus 870 ± 14 ml/m2; P = 0.007). A threshold
of less than 822 ml/m2 was correlated with DCI develop-
ment, whereas a global end-diastolic volume index above
921 ml/m2 was associated with the development of severe
pulmonary oedema. These finding suggest that maintain-
ing global end-diastolic volume index slightly above the
normal range may be effective to prevent hypovolemia
and severe pulmonary oedema, which may decrease the
risk of DCI.
Pulmonary complication, such as hospital-acquired pneu-
monia, cardiogenic or neurogenic pulmonary oedema,
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approximately 30 % of patients after SAH [142]. Acute re-
spiratory distress syndrome can affect 27 % of cases and is
independently associated with worse outcomes [143]. In
this clinical scenario, extra caution should be taken to avoid
fluid overload; however, diuretics might be dangerous be-
cause of the risk of hypovolemia-induced cerebral
ischaemia.
Hyponatremia (serum sodium of less than 135 mEq/
dl) is the most common electrolyte derangement after
SAH, occurring in up to 50 % of patients. There are two
possible mechanisms responsible for the development of
hyponatremia after SAH: (1) cerebral salt wasting (CSW)
and (2) the syndrome of inappropriate secretion of anti-
diuretic hormone (SIADH) [144]. These entities are fun-
damentally different in their pathogenesis; however, they
are difficult to distinguish in clinical practice and may
concur in the same patient [145]. Importantly, CSW
courses with intravascular volume contraction, which in-
creases the risk of DCI and poor outcome [145]. Like-
wise, the treatment of SIADH on the basis of fluid
restriction is not indicated, because of increased risk of
hypovolemia-associated cerebral infarction [146, 147].
Therefore, in clinical practice, the management of hypo-
natremia in the setting of SAH is based on the avoidance
of hypovolemia and the judicious repletion of volume
and sodium losses [144].
In a retrospective study in a single academic centre,
Wartenberg et al. found that a single occurrence of
hyperglycaemia, fever, or anaemia after aneurismal SAH
was independently predictive of poor outcome, even
after adjustment for traditional prognostic variables,
such as age, clinical grade, aneurysm size, re-bleeding,
and cerebral infarction [129].
Fever is the most common medical complication after
SAH and is associated with longer ICU and hospital
length of stays, worse functional outcomes, and higher
mortality [148, 149]. Although non-infectious fever is
common, especially in the presence of intraventricular
haemorrhage and poor-grade patients [150], it is strongly
recommended that frequent temperature checks and
careful assessment for possible infectious cause are
made. During the time window of vasospasm, it is desir-
able to maintain normothermia with antipyretic drugs,
followed by advanced fever control with surface cooling
or intravascular devices [151, 152]. In this situation, espe-
cial attention should be paid to detect and treat shivering.
The protocol for diagnosis and treatment of shivering has
been published elsewhere [153].
Ideally, blood sugar should be kept less than 200 mg/
dl and hypoglycaemia (less than 80 mg/dl) should be
strictly avoided. Both have been shown in microdialysis
studies to be associated with metabolic crisis and worse
neurological outcome [154, 155].Anaemia can be easily corrected, but blood transfusion
has been implicated with worse outcome after SAH [156,
157], including higher mortality, after adjustment for the
most common clinical indications of transfusion [158].
Although there is no clear threshold for transfusion in
patients with SAH, general ICU thresholds are not applic-
able for this population [7, 101, 159]. Dhar et al. [160], in
an elegant study using positron emission tomography
scan, demonstrated that transfusion in patients with
haemoglobin levels of less than 9 g/dl was the only inter-
vention capable of increasing global CBF and oxygen de-
livery, when compared with crystalloid bolus and induced
hypertension. The clinical applicability of these findings
needs to be addressed in a large trial because the study en-
rolled a small number of patients (38 in total) and had
only physiological endpoints.
Patients with poor-grade SAH are at high risk of ven-
ous thromboembolism [161]. Guidelines on manage-
ment of SAH suggest starting mechanical prophylaxis
with intermittent compression devices before aneurysm
treatment [8–10]. Pharmacologic thromboprophylaxis
seems to be safe if started within 12 to 24 hours after
aneurysm treatment [162].
Conclusions
Aneurysmal SAH is a complex neurovascular disease as-
sociated with multiple neurological and systemic compli-
cations and requires multidisciplinary specialised care,
best provided in high-volume centres. Patients who sur-
vive the initial bleed can deteriorate within 2 weeks, espe-
cially because of DCI. DCI is a syndrome with a complex
multifactorial pathophysiology that extends beyond the
historic explanation of angiographic vasospasm.
Although the risk of death and moderate and severe dis-
ability has decreased significantly over the last three de-
cades, the extent to which the prevalence of cognitive
deficits, poor quality of life, and daytoday functioning have
changed over the same period is completely undetermined.
Further studies should simultaneously tackle multiple
pathophysiological pathways, and long-term functional
outcomes shall be assessed by means of outcome measures
able to recognise subtle cognitive changes.
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